Your session is about to expire
← Back to Search
Cemiplimab + RP1 for Advanced Squamous Skin Cancer (CERPASS Trial)
CERPASS Trial Summary
This trial is testing if cemiplimab monotherapy is better than cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC.
CERPASS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCERPASS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CERPASS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have at least one tumor that can be measured and treated according to the study.I agree to provide samples of my tumor for review.I haven't had immune therapy for my condition in the last 3 years, except as part of initial treatment.I do not have active hepatitis B, hepatitis C, or HIV.I have had serious herpes infections or complications like eye or brain infections.I need regular anti-herpes medication.I have not received any live vaccines in the last 28 days.My skin cancer is advanced or has spread to other parts.I cannot or will not undergo surgery or radiation for my advanced disease.I have untreated brain tumors that are active.I can do all or most of my daily activities despite my cancer.I have an autoimmune disease treated with immunosuppressants in the last 5 years.I have had lung inflammation or pneumonitis in the last 5 years or needed steroids for it.I have been treated with a PD-1/PD-L1 inhibitor before.I have been treated with a virus-based cancer therapy before.I have not had any major surgery in the last 28 days.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many venues are currently hosting this experiment?
"Currently, there are 27 sites hosting this trial. These locations span from Columbus to Hackensack and Atlanta in addition to other cities. Participants should prioritize the closest location as a means of reducing travel needs if they choose to join the study."
Is enrollment for this research endeavor still available?
"Affirmative. According to the clinicaltrials.gov website, this study is actively recruiting patients who meet its criteria and has been doing so since October 8th 2019. 180 enrollees are required from 27 different medical sites for the trial that was most recently updated on August 5th 2022."
Has RP1 been given the stamp of approval by the Food and Drug Administration?
"After careful assessment, RP1's safety was scored a 2. This is because the medication has only been through Phase 2 trials, where some degree of safety could be ascertained but efficacy had yet to be verified."
What ailment is RP1 commonly prescribed to treat?
"RP1 is typically prescribed to patients with alk gene mutation, but it can also be beneficial for those suffering from advanced directives, malignancies, and metastatic cutaneous squamous cell carcinoma."
What is the current enrollment number for this medical experiment?
"Replimune Inc. has set the goal of recruiting 180 patients that meet the trial's requirements to participate in their study. The research is scheduled to take place at Ohio State University Comprehensive Cancer Center and John Theurer Cancer Center at Hackensack Univeristy Medical Center, among other sites."
Have there been any additional studies conducted on the effects of RP1?
"At present, 56 investigations are being conducted into RP1. 4 of these live trials have reached Phase 3 with Barcelona and California the most prominent locations for this research; however a total of 1738 sites around the world are running studies on this pharmaceutical treatment."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger